Admission for and mortality from primary venous thromboembolism in women of fertile age in Denmark, 1977-95
- 25 September 1999
- Vol. 319 (7213) , 820-821
- https://doi.org/10.1136/bmj.319.7213.820
Abstract
Epidemiological studies indicate that use of third generation oral contraceptives increases the risk of venous thromboembolism more than does use of second generation oral contraceptives.1−3 Critics have suggested that this finding may be confounded by indication, since third generation pills were considered to be safer and were therefore perhaps prescribed more often to women at high risk. If confounding by indication is the only explanation for the observed association, the incidence of venous thromboembolism in the population should not have changed when prescribing patterns changed from second generation to third generation pills with no increase in overall use of oral contraceptives. Vandenbroucke et al and Thomas reported increasing mortality from venous thromboembolism among young women in the Netherlands and in England and Wales from the mid-1980s to the 1990s, when the use of third generation pills was increasing.4 5 Since mortality from venous thromboembolism depends on both aetiological and prognostic factors, however, it may be more appropriate …Keywords
This publication has 5 references indexed in Scilit:
- Mortality from venous thromboembolism and myocardial infarction in young adults in England and WalesThe Lancet, 1996
- Mortality from venous thromboembolism and myocardial infarction in young women in the NetherlandsThe Lancet, 1996
- Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control studyBMJ, 1996
- Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.1995
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995